Siga Technologies, Inc. (SIGA) announced on Tuesday that it has entered into a licensing agreement with Vanderbilt University, located in Nashville, Tennessee. This agreement grants Siga the rights to a portfolio of preclinical, fully human monoclonal antibodies, which show promise as a treatment for a variety of orthopoxviruses, including smallpox and mpox.
The financial terms of this transaction remain undisclosed. As part of this agreement, Siga, a commercial-stage pharmaceutical company, has chosen to exercise its option for exclusive global rights to these antibodies.
These monoclonal antibodies are anticipated to potentially serve as standalone treatments or be used in conjunction with TPOXX.
